key: cord-0729925-lu1f9r7z
authors: Balkrishna, Acharya; Bhatt, Aarti Ben; Singh, Pratima; Haldar, Swati; Varshney, Anurag
title: Comparative Retrospective Open-label Study of Ayurvedic Medicines and Their Combination with Allopathic Drugs on Asymptomatic and Mildly-symptomatic COVID-19 Patients
date: 2021-05-21
journal: J Herb Med
DOI: 10.1016/j.hermed.2021.100472
sha: 2b30ae8e50e1b5f074fa379eec1490abc20745cc
doc_id: 729925
cord_uid: lu1f9r7z

INTRODUCTION: Treatment for COVID-19 was ambiguous in the beginning of the pandemic. At that time, the conventional medical system was grappling to cope with the rapidly spreading pandemic. The potential of Ayurveda, one of the branches of traditional Indian medicine (TIM), with a 5000 year old history, employing medicines derived from plants and other natural sources, against COVID-19 has been explored through a comparative retrospective open-label study. METHODS: Reported here are the remedial effects of Ayurvedic medicines alone or in combination with Allopathic treatment on 59 asymptomatic or mildly symptomatic COVID-19 patients, across multiple COVID-19 care centers in Ahmedabad, India. The patients were confirmed for COVID-19 infection through RT-qPCR of nasopharyngeal swabs. With informed consents from the patients, the sourced data was divided into ‘Allopathic and Ayurvedic’ [AlloAyur] (n = 41) and ‘Ayurvedic only’[Ayur] (n = 18) groups, based on the type of treatment the patients decided to receive, that is Ayurvedic medicines with Allopathic treatment or Ayurvedic medicines alone, respectively. Ayurvedic medicines included oral doses and nasal drops; the dosage and regime were decided based on the recommendations from Ayurvedic texts. The Allopathic medicines included Azithromycin, Vitamin-C and anti-histamines. Acetaminophen was also administered when necessary, by the attending physician. The patients were observed for symptomatic improvement. RESULTS: Primary outcome of this study was the symptomatic relief from COVID-19. Data collected over a period of two months, showed that more patients exhibited symptomatic relief in Ayur goup (83.33%) than in the AlloAyur group (48.78%) within the first 13 days of treatment. No visible adverse effects were observed. This indicated faster and safe symptomatic resolution among those treated with Ayurvedic medicines alone. CONCLUSION: Patients receiving only Ayurvedic medicines on average were symptomatically relieved faster than those receiving Allopathic and Ayurvedic medicines together.

COVID-19, the disease with influenza-like symptoms in mild to moderate cases and acute respiratory distress syndrome (ARDS)-like symptoms in severe cases, was first reported in December 2019 and soon spread across the world as a pandemic Zhu et al., 2020) . The new coronavirus, SARS-CoV-2, was identified to be the causative agent of this disease (Zheng, 2020) . The human cost alone of COVID-19 is distressing, let alone the socioeconomic and psychological burdens that has compounded the crisis. In the absence of any specific drug, management of COVID-19 relies on supportive care and non-specific treatments. WHO has recognized the long standing history of Traditional Medicine (TM) and understands it as an inherited legacy of repertoire of knowledge, skills and practices indigenous to a culture. TMs might or might not be explicable; nevertheless, used in the maintenance and improvement of health. China has reported several studies claiming the efficacy of Traditional Chinese Medicine (TCM) against COVID-19. In fact, three formulations, Lianhua Qingwen Capsule, Jinhua Qinggan Granule, and Xuebijing Injection have been made commercially available (Koe, 2020) . However, these TCMs are not free from skepticism as scientists outside China feel that these treatments might not be acceptable, particularly, in the absence of rigorous clinical data (Cyranoski, 2020) . Therefore attempts, at making TCM evidence based are being made through reviewing and meta-analyses of entries from various databases , case reports (Ren et al., 2020) and clinical trials (Lim, 2020; Xu and Zhang, 2020; Yang et al., 2020) . However, such assiduous efforts towards exploring the potentials of Ayurveda, the 5000-year-old system of Traditional Indian Medicine (TIM) against COVID-19 is grossly lacking. Based on pilot study and short-term clinical trials, The National Centre for Complementary and Integrative Health has reported the effectiveness of TIM against diseases like, osteoarthritis, rheumatoid arthritis, type 2 diabetes, ulcerative colitis and breast cancer ("Ayurvedic medicine: In depth," 2019).

Interestingly, Charak Samhita, one of the canonical texts of Ayurveda recognizes epidemic as janapadodhwamsa vikara, which literally translates into a disease that can destroy human habitations through massive death rate. Ayurvedic medicines were used to treat patients during 2006 outbreak of Chikungunya epidemic in India (Girija and Sivan, 2020) . From Ayurvedic point of view, COVID-19 is also an epidemic. However, except for a single case study report and a few recent trial reports on Ayurvedic treatment ameliorating COVID-19

infection (Girija and Sivan, 2020) , there is no contemporary scientific evidence suggesting the potential role of Ayurveda in preventing, containing and treating COVID-19 (Devpura et al., 2021; Wanjarkhedkar et al., 2020) . Ayurveda uses medicines derived from natural sources (Rastogi et al., 2020) . There are government advisories on using Ayurvedic treatments as immunity boosters and pragmatic planning for Ayurvedic intervention against COVID-19 (Ministry of AYUSH, 2020; Rastogi et al., 2020) . Nevertheless, there is a lack of evidence, generated through planned clinical studies on remedial effect of TIM against COVID-19.

Using the principles of Ayurveda, the authors have developed a prescription to treat COVID-19, which includes commercially available medicines, Divya Swasari Ras (DSR), Giloy Ghanvati (GG), Ashwagandha capsule (AC), Tulsi Ghanvati (TG) and Anu Taila (AT).

Constituents of these medicines are listed in Table 1. DSR is a poly herbo-mineral formulation; its constituents are mentioned in classical ancient Ayurveda, for the treatment of disorders related to respiratory tract such as, cough, bronchitis, asthma, rhinitis and excessive mucous formation which have been validated through preclinical studies (Balkrishna et al., 2020b) . DSR has been used in clinical settings at several Ayurvedic hospitals across India, on several thousand patients as registered in Patanjali Electronic Medical Records (PEMR).

J o u r n a l P r e -p r o o f GG is composed of natural compounds extracted from Tinospora cordifolia (traditionally, known as 'Giloy' or 'Guduchi' in India) . Computational studies have shown that tinocordiside, one of the major phytocompounds, of T. cordifolia docks into the ACE2-RBD complex, and therefore, has the potential to disrupt this critical interaction (Balkrishna et al., 2020a) . Besides, T. cordifolia is an excellent immunostimulant and effective against various microbial infections (Sinha et al., 2004) . Other major phytocomponents, reported in T. cordifolia, tinosporine, diterpenoid furano lactone, tinosporaside, cordifolide, cordifol, syringin, clerodane furano diterpene, tinosporidine, columbin, heptacosanol, b-sitosterol and tinosporide, cordifolioside A and syringin, possess immunomodulatory activity. In fact, tinosporin, diterpenoid has been claimed specially for the treatment of viruses including all subgroups of retroviruses (HIV-1, HIV-2), HTLV and Herpes simplex Virus (HSV) (Ghosh and Saha, 2012) .

ACs are composed of natural compounds from Withania somnifera (traditionally, known as Ashwagandha in India). Like tinocordiside, withanone, one of the major phytochemicals present in W. somnifera could also bind at the interface of SARS-CoV-2 spike (S) protein receptor binding domain (RBD) and host ACE2 receptor complex, as suggested by docking and molecular dynamic simulation studies. This disrupted the ACE2-RBD interaction, critical for the entry of virus into host cell (Balkrishna et al., 2021c) . Other computational studies have reported that withanone can also target SARS-CoV-2 main protease (M pro ) and host transmembrane TMPRSS2 (Kumar et al., 2020a (Kumar et al., , 2020b . Ocimum sanctum (Tulsi) provides a vast array of health benefits, anti-viral effects, being one of them (Cohen, 2014; Mahajan et al., 2013; Pattanayak et al., 2010) . O. sanctum is very rich in phytochemicals. It has been discovered that scutellarein, a natural flavone found in O. sanctum, docks into the active site of RNA dependent RNA Polymerase (RDRP) enzyme of SARS-CoV-2 coronavirus, which is indispensable for viral multiplication (unpublished data).

J o u r n a l P r e -p r o o f Nasal congestion, anosmia, runny nose, sneezing, fever and whole-body fatigue are symptoms associated with COVID-19 infection. In Ayurvedic practice, Anu Taila is used for Nasya processes (nasal drops) to reduce inflammation in nasal passage and respiratory tract.

The polyherbal components of Anu Taila, Aegle marmelos (Nicolis et al., 2009; Pynam and Dharmesh, 2018; Rajaram et al., 2018) , Asparagus racemosus (Gautam et al., 2009; Kanwar and Bhutani, 2010; Tiwari et al., 2017) , Aquilaria agallocha (D. , Cedrus deodara (Gupta et al., 2011) , Cinnamomum verum (Hagenlocher et al., 2013) , Coleus vettiveroides , Cyperus esculentus (Krichene et al., 2016) , Cyperus rotundus (Kamala et al., 2018) , Desmodium gangeticum (A. K. , Elettaria cardamomum (Majdalawieh and Carr, 2010) , Embelia ribes (Shirole et al., 2015) , Glycyrrhiza glabra (Lee et al., 2019) , Nelumbo mucifera (Zhao et al., 2010) , Ocimum sanctum (Choudhury et al., 2014) , and Pogostemon cablin (Yang et al., 2018) have antiinflammatory potential and can ameliorate pro-inflammatory cytokines such as IL-1β, TNFα, IFN-γ, IP-10, MCP-1, IL-4, and IL-8.

Despite, all this information, clinical research data on the effects of Ayurvedic medicines on COVID-19 are almost non-existent. Therefore, a comparative retrospective open-label study on the COVID-19 positive patients in different COVID-19 care centers across Ahmedabad, Gujarat, India was conducted to evaluate the potential remedial effects of the Ayurvedic medicines on this disease.

With informed consent, the medical data of 59 patients who chose to be given either Allopathic treatment in combination with Ayurvedic medicines ('AlloAyur' group) (n=41) or Ayurvedic medicines alone ('Ayur' group) (n=18) between May 2020 and June 2020 was mined. These patients, after being confirmed as COVID-19 positive through RT-qPCR of J o u r n a l P r e -p r o o f nasal swab samples, were admitted at various COVID-19 care centers in Ahmedabad, Gujarat, India. Data was sourced from medical record departments (MRDs) of these care centers. Clinically, these cases were asymptomatic to mildly symptomatic in nature. None of these patients had any international travel history. Primary outcome of this study was symptomatic resolution of COVID-19 infection.

Patients between 10-80 years of age from either gender, who were either asymptomatic or demonstrated one of the clinical symptoms, namely, fever, cough, headache, fatigue, sore throat, nasal congestion and dyspnea (mild). All patients were verified to be positive for COVID-19 through RT-qPCR for nasopharyngeal swab tests. Ability to give informed consent was the other important inclusion criteria.

Patients with severe COVID-19 and ARDS symptoms and any co-morbid condition, such as, end stage renal disease (ESRD), decompensated heart failure and decompensated liver failure, responsible for life expectancy less than a year were excluded from the study.

The study completion criteria included regaining normal body temperature, relief from cough, headache, fatigue, sore throat, nasal congestion and/or dyspnea. Alleviation of COVID-19 symptoms were monitored for at least 72 hours to ensure no relapses before discharge of the patients were approved from the care center and concomitantly, from the study.

The Allopathic medicines administered were based on the symptoms exhibited by the patients. Under the treatment regime of Allopathic medicines, Azithromycin along with Vitamin-C and anti-histamine were given. Acetaminophen was also administered, when J o u r n a l P r e -p r o o f 8 necessary, by the attending physician. Ayurvedic medicines administered were based on the principles mentioned in the texts on Traditional Indian Medicine (TIM). Total daily doses of 2 g each of DSR and GG and 1 g each of AC and TG, respectively, were administered orally with lukewarm water. DSR was given 30 min before meals. The rest were given 30 min after meal. 4 drops of AT were applied to each nostril 1 h before breakfast. A daily dosage regime for these Ayurvedic medicines is provided in Table 2 

At baseline, the clinical symptoms of the patients such as, body temperature, cough, fatigue, headache, sore throat, nasal congestion and dyspnea were monitored. Subsequently, these parameters were regularly tracked along with any other visible symptoms or any side-effects of the treatment.

Overall and group-wise age distributions are represented as percent COVID-19 cases in different age ranges. Gender distribution within each age group is shown as percent male/female of the total patients within that particular group and is shown as proportional bar 

Although the authors intended to include asymptomatic to mildly symptomatic patients, the patient pool that was observed presented mostly mildly symptomatic cases. 53 out of 59 patients (89.8%) were mildly symptomatic. The intervention was to cover a wide age range and thus, included patients between 10-80 years, accordingly, the dosages varied. For patients below 15 years, half of the dose mentioned in table 1 was administered. Since, patient consent was the key modulator in grouping, we eventually had 41 patients in the AlloAyur group and 18 in the Ayur group. Sizes of the groups was practically an outcome of the decisions the patients took. The study plan, inclusion and exclusion criteria and number of asymptomatic and mildly symptomatic cases in each group are mentioned in Figure 1 . No patients with severe symptoms, who required respiratory aids were included. Such patients would be beyond their judgement for informed consent or taking any decision. Patients with acute respiratory distress syndrome (ARDS) were also excluded because of the reasons mentioned earlier for those with severe symptoms. In order to keep the readouts of our observations clean and as much noise-free as possible, patients with co-morbidities responsible for life expectancies less than a year were also excluded.

The authors analyzed the age distribution of the COVID-19 cases that were followed in this study and found that most of them (62.71%) were in the age bracket of 31-55 years, followed by 20.34% and 11.86 % in the age groups of 18-30 and > 55 years, respectively.

Only 5% cases were observed among patients < 18 years of age (Figure 2A) . Similar age distribution was observed separately for both the study groups ( Figure 2B) . No mortality was reported. It was found that male patients under the authors observation were more prone J o u r n a l P r e -p r o o f to COVID-19 infection in all the age groups except beyond 55 years where the trend switched with 57.14 % patients to be female and 42.86% patients to be male. 66.67 % of total patients below 18 years and between 18-30 years of age, were male and 33.33 % were females.

Similarly, 62.16 % of total patients between 31-55 years were male while 37.84% were females ( Figure 2C) . In order to rule out the possibility of skewed gender distribution affecting the primary observation on remedial effects of Ayurvedic medicines on COVID-19 infection, the male-female percentages in the AlloAyur and Ayur groups were analyzed. The gender distribution within these groups were similar; AlloAyur group had 68 % male and 32 % and Ayur group had 72 % male and 28 % female ( Figure 2D ).

The most encouraging observation is the trend of expedited symptomatic relief in the Ayur group where the patients were on Ayurvedic medicines only. 15 out of 18 patients in this group were relieved from COVID-19 symptoms within the first 13 days of treatment exhibiting 83.33% recovery. In comparison, out of 41 patients in the AlloAyur group, 20 experienced symptomatic relief making a 48.78 % recovery within the first 13 days ( Figure   3A ). A Kaplan Meier curve was plotted to quantitatively visualize the pattern of recovery efficiencies within the AlloAyur and Ayur groups. Up to 9 days of treatment, similar proportion of recovery was seen in both the groups. However, the recovery proportion was visibly more in the Ayur group, than the AlloAyur group, by day 15 of the treatment. This proportion became 1 by day 21, indicating 100% recovery by this time in the Ayur group.

Unlike the Ayur group, the recovery proportion in the AlloAyur group by day 21 was 0.7, demonstrating visible lagging behind. However, the calculated Mantel-Cox log rank p value was 0.0854, suggesting that the difference between the two curves was not statistically significant. This was likely to be the effect of non-uniformity of the group sizes and overall small sample size. Therefore, a statistically significant remedial effect on COVID-19 J o u r n a l P r e -p r o o f infection in the Ayur group, in comparison to the AlloAyur group, could not be deduced. A bigger sample size with uniformity in patient distribution is required to establish the statistical significance and give verity to this observation. In addition, the other important observation was the absence of any adverse side-effects associated with these Ayurvedic medicines in this study.

The main aim of this study was to evaluate the potential of Ayurvedic medicines against COVID-19 infection. The premise for this study has been recognition of epidemic in Ayurveda, mention of treatments for ailments with symptoms resembling those of mild to moderate cases of COVID-19 and reports on anti-viral, immune-modulatory and antiinflammatory effects of the Ayurvedic medicines being studied or their individual constituents (Balkrishna et al., 2021b (Balkrishna et al., , 2020b (Balkrishna et al., , 2020a Choudhury et al., 2014; Gautam et al., 2009; Gupta et al., 2011; Hagenlocher et al., 2013; Kamala et al., 2018; Kanwar and Bhutani, 2010; Lee et al., 2019; Mahajan et al., 2013; Majdalawieh and Carr, 2010; Nicolis et al., 2009; Pattanayak et al., 2010; Pynam and Dharmesh, 2018; Rajaram et al., 2018; Sinha et al., 2004; Tiwari et al., 2017; A. K. Yadav et al., 2013) .

Ayurveda is a well-documented form of medicine with historical roots. The formulations and dosage of the medicines used in this study were based on the information from different ancient texts of Ayurveda. Formulation and dosage of DSR was adopted from Bhav Prakash

Pharmacopoeia of India (Namjoshi, 2003; Pharmacopoeia Commission for Indian Medicine & Homeopathy, 2016) . Similarly, information on AC, GG and TG was obtained from Bhav Prakash Nighantu, on page numbers 393, 269 and 509, respectively (Lucas, 2017) .

Composition and dosage recommendations for AT were guided from Ayurved Sar Sangrah (page number 679) (Vaidyanath, 2017) and Ayurvedic Pharmacopoeia of India can ameliorate asymptomatic to mildly symptomatic cases of COVID-19. Thus, instead of a pre-meditated design, this study was shaped entirely by the patients' discretion after they were made aware of the objective of the study. This reflected as the apparent non-uniformity of group sizes. The authors ensured through the exclusion criteria that no critical case was included. Nevertheless, this study has offered observations encouraging enough to consider the potentials of Ayurvedic medicines against the novel coronavirus and pursue similar studies on a bigger scale.

This study was supervised by suitably qualified physicians. The risks and burdens of the Ayurvedic interventions used in this study were judged prior to the treatments being tested.

This complied with one of the provisions of the World Medical Association (WMA, declaration of Helsinki) that allows unproven interventions to be studied (Carlson et al., 2004) . Moreover, the medicines used in this study have their firm roots in Ayurveda, the ancient Indian science of medicine, with the safety of usage well documented therein. The formulations and recommended applications of the Ayurvedic medicines used here are already mentioned in Ayurveda, implicating that they have already been in use without toxicity issues, as also evident from absolute lack of visible side-effects in the patients. Three patients had Diabetes mellitus, one was hypertensive and two had both Diabetes mellitus and hypertension yet responded positively towards the treatment without any adverse effects.

The authors observed that the patients who decided to take only Ayurvedic medicines were relieved of their symptoms faster as compared to those who chose to supplement their J o u r n a l P r e -p r o o f 13 Allopathic treatments with Ayurvedic medicines. This was evident from the higher percentage of patients on Ayurvedic medicines only recovering by the thirteenth day of treatment as compared to those who received both Allopathic and Ayurvedic medicines. All the patients on Ayurvedic medicines were completely relieved of their symptoms by 21 days of treatment while, the recovery proportion was 0.7 among those who decided to take the combinatorial treatment of Allopathic and Ayurvedic medicines. Due to the small sample size, this observation with a log rank p value of 0.0854 was not quite statistically significant, nevertheless, without missing to establish an expedited time of symptomatic relief from COVID-19 with only Ayurvedic treatment.

COVID-19 causes viraemia after entering the body and the main clinical manifestations are fever, pharyngalgia, fatigue, diarrhea and other non-specific symptoms. The phytochemicals present in the Ayurvedic medicines mentioned here work at different steps of viraemia, such as, to prevent viral entry (Balkrishna et al., 2021b (Balkrishna et al., , 2020a , to inhibit viral replication (unpublished data), and to reduce inflammation of the respiratory tract and strengthen immunity (Balkrishna et al., 2020b) . Observations from a randomized placebo controlled pilot clinical study, that evaluated the effectivity of these medicines on a slightly larger asymptomatic to mildly symptomatic patient pool, upholds our findings from this study (Devpura et al., 2021) . For better patient compliance, AC, GG and TG were combined and formulated into a tablet, called 'Coronil' and subsequently, its pharmacological effects against SARS-CoV-2 spike protein have been confirmed through in-vitro ((Balkrishna et al., 2021a) and in-vivo (Balkrishna et al., 2020c) studies.

The observation that only Ayurvedic medicines were capable of comparatively faster symptomatic resolution of COVID-19 relative to Allopathic-Ayurvedic combinatorial treatment actually testifies the newly emerging concept of herb-drug interactions (HDI) (Borse et al., 2019) . Allopathy and Ayurvedic medicines have different pharmacokinetic and pharmacodynamic properties. Allopathy medicines work as single target agents, while Ayurvedic formulations, being composed of mainly, phytochemicals, are capable of multitargeting. With an increase in the acceptance of integrative treatment approach, combining conventional and complementary principles, better understanding of HDIs has become necessary, because, this combination does not always lead to synergism (Borse et al., 2019) .

In this case, the combinatorial treatment is likely to have experienced antagonistic effect as evident from visibly less effective symptomatic resolution of COVID-19 in the AlloAyur group.

Non-uniform sizes of the study groups was a prominent drawback of this study.

However, the two groups were comparable in terms of everything else at the baseline, except for their sizes. In fact, the gender distribution within the two groups (68 % male, 32 % female in AlloAyur group versus 72 % male, 28 % female in Ayur group) clearly reflects that they are comparable in terms of the disease prevalence with respect to gender. COVID-19 positive cases included in this study were asymptomatic or mildly symptomatic, therefore, the efficacy of Ayurvedic medicines on the severe patients and patients with co-morbidities require further evaluation as the observations from this trial cannot be generalized to them.

Moreover, the study was non-blind and was based on patient preference rather than random allocation of study groups. These drawbacks might lead to lack of balance on unmeasured characteristics. Nevertheless, the observations from this study do serve as forerunner for a randomized study with bigger sample size in future, which could address these limitations efficiently.

In conclusion, this study demonstrated that in comparison of Allopathic to Ayurvedic combinatorial intervention, Ayurvedic medicine alone can reduce the time to symptomatic recovery in asymptomatic and mildly symptomatic COVID-19 patients. This study also 

Coronil , A Tri-herbal Formulation , Attenuates Spike-protein Mediated SARS-CoV-2 Viral entry into Human Alveolar Epithelial Cells and Pro-inflammatory Cytokines Production by Inhibiting Spike protein-ACE-2 Interaction

Giloy Ghanvati (Tinospora cordifolia (Willd.) Hook. f. and Thomson) Reversed SARS-CoV-2 Viral Spike-Protein Induced Disease Phenotype in the Xenotransplant Model of Humanized Zebrafish

Withanone from Withania somnifera Attenuates SARS-CoV-2 RBD and Host ACE2 Interactions to Rescue Spike Protein Induced Pathologies in

Tinocordiside from Tinospora cordifolia (Giloy) May Curb SARS-CoV-2 Contagion by Disrupting the Electrostatic Interactions between Host ACE2 and Viral S-Protein Receptor Binding Domain

Ocimum sanctum leaf extracts attenuate human monocytic (THP-1) cell activation

Tulsi -Ocimum sanctum: A herb for all reasons

China is promoting coronavirus treatments based on unproven traditional medicines

Randomized Placebo-Controlled Pilot Clinical Trial on the Efficacy of Ayurvedic Treatment Regime on COVID-19 Positive Patients

Immunomodulatory activity of Asparagus racemosus on systemic Th1/Th2 immunity: Implications for immunoadjuvant potential

Tinospora cordifolia: One plant, many roles

Ayurvedic treatment of COVID-19/SARS-CoV-2: A case report

Phytochemistry and Pharmacology of Cedrus Deodera: an Overview

Cinnamon extract inhibits degranulation and de novo synthesis of inflammatory mediators in mast cells

Plants in traditional medicine with special reference to

Effects of Chlorophytum arundinaceum, Asparagus adscendens and Asparagus racemosus on pro-inflammatory cytokine and corticosterone levels produced by stress

It ' s official : China adds three TCM formula to COVID-19 standard therapy

Withanone and withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells

Withanone and caffeic acid phenethyl ester are predicted to interact with main protease (Mpro) of SARS-CoV-2 and inhibit its activity

Effects of glycyrrhizin on lipopolysaccharide-induced acute lung injury in a mouse model

Traditional Chinese herbal medicine for treating novel coronavirus (COVID-19) pneumonia: Protocol for a systematic review and meta-Analysis

TCM and COVID-19 : China conducting trials to test efficacy and safety of traditional herbal interventions

China-conducting-trials-to-test-efficacy-and-safety-of-traditional-herbal-interventions

Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle

Bhav Prakash Nighantu (Indian Materia Medica of Shri Bhavamishra)

Extracts of Coleus forskohlii relieves cough and asthma symptoms via modulating inflammation and the extracellular matrix

A phytopharmacological overview on Ocimum species with special emphasis on Ocimum sanctum

In vitro investigation of the potential immunomodulatory and anti-cancer activities of black pepper (Piper nigrum) and cardamom (Elettaria cardamomum)

Ayurveda's immunity boosting measures for self care during COVID 19 crisis. Ministry of AYUSH, Government of India

The Ayurvedic Formulary of India, The Ayurvedic Formulary of India. Govt. of India, Ministry of Health & Family Welfare

Modulation of expression of IL-8 gene in bronchial epithelial cells by 5-methoxypsoralen

Ocimum sanctum Linn. A reservoir plant for therapeutic applications: An overview

The Ayurvedic Pharmacopoeia of India, First

Antioxidant and anti-inflammatory properties of marmelosin from Bael (Aegle marmelos L.); Inhibition of TNF-α mediated inflammatory/tumor markers

Anti-inflammatory profile of Aegle marmelos (L) Correa (Bilva) with special reference to young roots grown in different parts of India

COVID-19 pandemic: A pragmatic plan for ayurveda intervention

Traditional Chinese medicine for COVID-19 treatment

Embelia ribes ameliorates lipopolysaccharide-induced acute respiratory distress syndrome

Tinospora cordifolia (Guduchi), a reservoir plant for therapeutic applications: A Review

Adjuvant effect of Asparagus racemosus Willd. derived saponins in antibody production, allergic response and pro-inflammatory cytokine modulation

Ayurved Sar Sangrah. Shri Vaidyanath Ayurved Bhawan Ltd

A prospective clinical study of an Ayurveda regimen in COVID 19 patients

Traditional Chinese Medicine treatment of COVID-19

Novel anti-inflammatory phytoconstituents from Desmodium gangeticum

Molecular Docking and ADME Studies of Natural Compounds of

Agarwood Oil for Topical Anti-Inflammatory Activity

Pogostone attenuates TNF-α-induced injury in A549 cells via inhibiting NF-κB and activating Nrf2 pathways

Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): A review and perspective

Neferine, a bisbenzylisoquinline alkaloid attenuates bleomycin-induced pulmonary fibrosis

SARS-CoV-2: An emerging coronavirus that causes a global threat

A novel coronavirus from patients with pneumonia in China